← All Sponsors
SPONSOR

Comprehensive Cancer Center Munich (CCCM)

Total Trials
1
Recruiting
1
Phases
N/A
Conditions studied: Urothelial Cancer
NCT06657157
Recruiting

Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma

Urothelial Cancer
Germany View Trial →